First-line Therapy with Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients with Chronic Lymphocytic Leukemia (CLL) with Mutated IGHV gene and Non-del(17p)
Cyclophosphamide, Fludarabine, Ibrutinib, Obinutuzumab
The goal of this clinical research study is to learn if the combination of ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab can help control CLL. The safety of this drug combination will be also studied.
Disease Group: Leukemia
Treatment Agent: Cyclophosphamide, Fludarabine, Ibrutinib, Obinutuzumab
Treatment Location: Only at MD Anderson
Sponsor: Genentech,Pharmacyclics, Inc.
IRB Review and Approval Date: 03/18/2016
Recruitment Status: Open
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: